Hepatocellular type II fibrinogen inclusions in a patient with severe COVID-19 and hepatitis

Fraga, Montserrat; Moradpour, Darius; Artru, Florent; Romailler, Élodie; Tschopp, Jonathan; Schneider, Antoine; Chtioui, Haïthem; Neerman-Arbez, Marguerite; Casini, Alessandro; Alberio, Lorenzo; Sempoux, Christine

doi:10.1016/j.jhep.2020.06.021

Cited by 12 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Direct infection of liver cell types including cholangiocytes[ 28 , 29 ] and hepatocytes[ 30 ] has been suggested, but the latter requires confirmatory testing since single cell RNA sequencing has shown relatively sparse hepatocyte expression of the receptors necessary for viral uptake[ 31 ]. However, given the profound multi-systemic involvement of COVID-19, particularly in the severe and critical forms of disease, liver injury is likely to be multifactorial with contributions from systemic inflammation, intrahepatic immune activation, microvascular thrombosis, perturbations of the gut-liver-axis, and drug toxicity[ [32] , [33] , [34] , [35] , [36] ]. In our cohort, patients who suffered acute hepatic decompensation had a 2-fold increased rate of mortality compared to those without and case fatality strongly correlated with degree of organ failure.…”

Section: Discussionmentioning

confidence: 99%

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study

Marjot¹,

Moon²,

Cook³

et al. 2021

Journal of Hepatology

406

618

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study

Marjot¹,

Moon²,

Cook³

et al. 2021

Journal of Hepatology

406

618

View full text Add to dashboard Cite

show abstract

“…Given the profound multi-systemic involvement of COVID-19, particularly in the severe and critical forms of disease, liver injury is likely to be multifactorial with contributions from systemic inflammation, intrahepatic immune activation, microvascular thrombosis, hepatic congestion, perturbations of the gut-liver-axis, as well as drug toxicity. [45] , [46] , [47] , [48] The prognostic significance of deranged biochemistry in COVID-19 remains unresolved 49 ; some groups have demonstrated a strong correlation with duration of hospitalisation, organ failure and intensive care unit admission 37 , 41 , 50 whilst others have failed to observe any significant associations with outcome. 39 , 40 …”

Section: Liver Injury Secondary To Covid-19mentioning

confidence: 99%

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

et al. 2020

View full text Add to dashboard Cite

During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, EASL and ESCMID published a position paper to provide guidance for physicians involved in the care of patients with chronic liver disease. While some healthcare systems are returning to a more normal routine, many countries and healthcare systems have been, or still are, overwhelmed by the pandemic, which is significantly impacting on the care of these patients. In addition, many studies have been published focusing on how COVID-19 may affect the liver and how pre-existing liver diseases might influence the clinical course of COVID-19. While many aspects remain poorly understood, it has become increasingly evident that pre-existing liver diseases and liver injury during the disease course must be kept in mind when caring for patients with COVID-19. This review should serve as an update on the previous position paper, summarising the evidence for liver disease involvement during COVID-19 and providing recommendations on how to return to routine care wherever possible.

show abstract

“…The increased fibrin formation and breakdown correlated with the high level of D-dimers observed in the COVID-19 patients with the worst outcomes . The increasing levels of FGG in severe cases might be due to liver injury, impairing hepatic fibrinogen secretion with acquired fibrinogen storage disease (Fraga, 2020).…”

Section: Ll Open Access Isciencementioning

confidence: 99%

Proteomic investigation reveals dominant alterations of neutrophil degranulation and mRNA translation pathways in patients with COVID-19

Bankar¹,

Suvarna²,

Ghantasala³

et al. 2021

iScience

View full text Add to dashboard Cite

The altered molecular proteins and pathways in response to COVID-19 infection are still unclear. Here, we performed a comprehensive proteomics-based investigation of nasopharyngeal swab samples from COVID-19 patients to study the host response by employing simple extraction strategies. Few of the host proteins such as Interleukin-6, L-lactate dehydrogenase, C-reactive protein, Ferritin and Aspartate aminotransferase were found to be up-regulated only in COVID-19 positive patients using targeted Multiple Reaction Monitoring studies. The most important pathways identified by enrichment analysis were neutrophil degranulation, interleukin-12 signaling pathways and mRNA translation of proteins thus providing the detailed investigation of host response in COVID-19 infection. Thus, we conclude that mass spectrometry-detected host proteins have a potential for disease severity progression; however, suitable validation strategies should be deployed for the clinical translation. Furthermore, the in-silico docking of host proteins involved in the interleukin-12 signaling pathway might aid in COVID-19 therapeutic interventions.

show abstract

Hepatocellular type II fibrinogen inclusions in a patient with severe COVID-19 and hepatitis

Cited by 12 publications

References 22 publications

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

Proteomic investigation reveals dominant alterations of neutrophil degranulation and mRNA translation pathways in patients with COVID-19

Contact Info

Product

Resources

About